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EMCDDA–Europol Joint Report on a new psychoactive 
substance: N-phenyl-N-[1-(2-phenylethyl)
piperidin-4-yl]-furan-2-carboxamide (furanylfentanyl)
In accordance with Article 5 of Council Decision 2005/387/JHA on 
the information exchange, risk assessment and control of new 
psychoactive substances
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol national units and the 
national competent authorities of the European Medicines Agency.
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
the ‘Council Decision’) stipulates that ‘Where Europol and the 
EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State 
on a new psychoactive substance merits the collection of 
further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint 
Report.’ The Joint Report shall be submitted to the Council of 
the European Union, the European Medicines Agency (EMA), 
and the European Commission.
In November 2016, the EMCDDA and Europol examined the 
available information on the new psychoactive substance 
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-furan-2-
carboxamide, commonly known as furanylfentanyl, through 
a joint assessment based upon the following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information 
collected on furanylfentanyl satisfied criteria 4 and 6. The two 
agencies therefore concluded that sufficient information had 
been accumulated to merit the production of a Joint Report on 
furanylfentanyl as stipulated by Article 5.1 of the Council 
Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, on 
16 November 2016 the EMCDDA and Europol launched 
a procedure for the collection of information on 
furanylfentanyl, in order to prepare the Joint Report. The 
information was collected mainly through the Reitox National 
Focal Points in the Member States, Turkey and Norway as well 
as the Europol National Units. In addition, the EMA collected 
information through the national competent authorities 
responsible for human and veterinary medicinal products in 
the Member States as well as in Norway, Iceland and 
Liechtenstein. The EMA also provided information as relevant 
to the centralised procedure for authorising medicinal 
products. The information collection process was largely 
concluded by 28 December 2016.
(1) OJ L 127, 20.5.2005, p. 32.
Information collected by Europol
Europol asked the Europol National Units to provide 
information on:
 ¡ the level of production of furanylfentanyl in their country;
 ¡ the level of distribution of furanylfentanyl in their country;
 ¡ the level of trafficking of furanylfentanyl in their country, 
both for internal, transit or export purposes;
 ¡ the number of seizures of furanylfentanyl in their country, 
the total amount of the seizures, country of origin, details 
on the physical forms (including photos);
 ¡ the role of organised crime, or criminal groups, in the 
production, distribution and trafficking of furanylfentanyl in 
their country; and,
 ¡ any known aspect of violence and/or money laundering 
relating to the production and trafficking of furanylfentanyl.
Europol received responses from 19 Member States (2) and 
Norway.
Information collected by the EMA
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the Member 
States, Norway, Iceland, and Liechtenstein, provide 
information on whether:
 ¡ the new psychoactive substance furanylfentanyl has 
obtained a marketing authorisation;
 ¡ the new psychoactive substance furanylfentanyl is the 
subject of an application for a marketing authorisation; and,
 ¡ a marketing authorisation that had been granted in respect 
of the new psychoactive substance furanylfentanyl has 
been suspended.
Twenty-four countries provided a response to the EMA’s 
request regarding human and/or veterinary medicinal 
products (3). The EMA also provided information as relevant to 
the centralised procedure for authorising human and 
veterinary medicinal products.
Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
(2) In alphabetical order: Austria, Belgium, Croatia, Cyprus, Czech Republic, 
Denmark, Estonia, Finland, Germany, Greece, Hungary, Ireland, Italy, Latvia, 
Lithuania, Luxembourg, Slovenia, Spain and Sweden.
(3) Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Hungary, 
Iceland, Ireland, Latvia, the Netherlands, Norway, Slovakia, Spain and Sweden 
provided a response in relation to human and veterinary medicinal products. 
Croatia, Czech Republic, Italy and the United Kingdom provided a response in 
relation to human medicinal products. France, Poland, Portugal and Slovenia 
provided a response in relation to veterinary medicinal products.
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products in the European Union, the EMA also requested 
information on whether the new psychoactive substance 
furanylfentanyl is used to manufacture a medicinal product:
 ¡ which has been granted a marketing authorisation;
 ¡ for which an application has been made for a marketing 
authorisation; and,
 ¡ for which a marketing authorisation has been suspended 
by a competent authority.
Twenty-four countries (4) provided a response to the EMA’s 
request in this regard. The EMA also provided information as 
relevant to the centralised procedure for authorising human 
and veterinary medicinal products.
Information collected by the EMCDDA
The EMCDDA collected information through:
1. a structured questionnaire to the Reitox National Focal 
Points. The EMCDDA received replies from all 28 Member 
States, as well as Turkey and Norway;
2. reports previously provided to the European Union Early 
Warning System, including EMCDDA–Europol Reporting 
Forms and Progress Reports and Final Reports;
3. routine monitoring of open source information;
4. a specific information request to the World Health 
Organization on whether or not furanylfentanyl is under 
assessment by the United Nations system; and,
5. a search of open source information conducted specifically 
for the production of the Joint Report which included: 
scientific and medical literature, official reports, grey 
literature, internet drug discussion forums and related 
websites (hereafter, ‘user websites’), and, online vendors 
selling furanylfentanyl.
Thus, the information included in sections 3.2.1 and 3.3 of the 
Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 
3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information 
included in sections 3.8.3 (in part), 4.1, 4.2 and 4.3 was 
provided by the EMA. Images of the seizures and collected 
samples reported to the EMCDDA and Europol are provided in 
Annex 1 and Annex 2, respectively.
(4) Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Hungary, 
Iceland, Ireland, Latvia, the Netherlands, Norway, Slovakia, Spain and Sweden 
provided a response in relation to human and veterinary medicinal products. 
Croatia, Czech Republic, Italy and the United Kingdom provided a response in 
relation to human medicinal products. France, Poland, Portugal and Slovenia 
provided a response in relation to veterinary medicinal products.
 3.  Information required by Article 5.2 of 
the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4, 
below, are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
 3.1  Chemical and physical description, including the 
names under which the new psychoactive 
substance is known (Article 5.2(a) of the Council 
Decision)
Chemical description and names
Furanylfentanyl belongs to the 4-anilidopiperidine class of 
synthetic opioids. This class also includes fentanyl, 
acetylfentanyl (5)(6) and a number of other fentanils, which are 
internationally controlled.
Furanylfentanyl differs from fentanyl due to the presence of 
a furan ring in place of an ethyl group attached to the carbonyl.
The molecular structure, molecular formula, and molecular 
mass of furanylfentanyl are provided in in Figure 1.
Furanylfentanyl has one positional isomer, which is 
3-furanylfentanyl. In 3-furanylfentanyl, the carboxamide is 
attached to the 3-position of the furan ring.
The synthesis of furanylfentanyl was first described in a 1986 
patent (Huang et al., 1986).
Commonly used names: furanylfentanyl
Systematic (IUPAC) name: N-phenyl-N-[1-(2-phenylethyl)
piperidin-4-yl]-furan-2-carboxamide
Chemical Abstracts names: N- phenyl- N- [1- (2- phenylethyl) - 4- 
piperidinyl] - 2- furancarboxamide
Other chemical names: 1-(2-phenylethyl)-4-(N-phenyl-2-
furoylamido)piperidinium, N-(1-phenethylpiperidin-4-yl)-N-
phenylfuran-2-carboxamide, N-phenyl-N-[1-(2-phenylethyl)
piperidin-4-yl]-2-furamide, N-(1-(2-phenylethyl)-4-piperidinyl)-
N-phenylfuran-2-carboxamide
(5) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide. 
(6) Schedule I and IV of the 1961 United Nations Single Convention on Narcotic 
Drugs.
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Other names and code names: FU-F, 2-furanoylfentanyl, 
despropionyl furanoyl fentanyl, furanyl fentanyl, Furanylfenta 
and furanyylifentanyyli (Finnish).
Names for products in herbal form seized in Poland are: 
‘talizman motocyklisty’, ‘Talizman 0,5g-Ziel’ and ‘Talizman 
1,0g – Ziel’ (section 3.2.2).
Chemical Abstracts Service (CAS) registry numbers (7):
101345-66-8: base
101365-56-4: hydrochloride salt
IUPAC International Chemical Identifier Key (InCHI Key) (8):
FZJVHWISUGFFQV-UHFFFAOYSA-N
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the 
CAS registry numbers listed above. The searches returned no 
hits.
Physical description
Furanylfentanyl contains one basic nitrogen atom in the 
piperidine ring which can readily form salts with organic or 
inorganic acids.
There is no solubility data on furanylfentanyl or its 
hydrochloride salt; due to its similarity to fentanyl, the free 
(7) The Chemical Abstract Service Registry Number (CAS RN) is a unique 
numeric identifier assigned by the Chemical Abstract Service Division of the 
American Chemical Society to a specific, single chemical substance.
(8) InChI Key is a unique, non-proprietary structural identifier of chemical 
substances useful in electronic sources.
base could be expected to be sparingly soluble in water; the 
hydrochloride and citrate salt could be expected to have 
greater aqueous solubility.
Furanylfentanyl is expected to be lipophilic. Similarly to 
acryloylfentanyl (EMCDDA, 2016), it could be expected that 
carry-over of traces of the substance during sample handling 
and analysis could be problematic (Degg, 2014).
Furanylfentanyl has been typically seized in powder form 
however it has also been detected to a lesser extent in liquid 
(often in nasal spray bottles), tablet and herbal material form. 
A more detailed description of seizures and collected samples 
can be found in section 3.2.1 and section 3.2.2.
Detection and analysis
Methods documented in the literature for the detection of 
furanylfentanyl include: liquid chromatography – tandem 
mass spectrometry (LC-MS/MS), liquid chromatography – 
high resolution-mass spectrometry (LC-HRMS) (Helander et 
al., 2016; Mohr et al., 2016), gas chromatography – mass 
spectrometry (GC-MS), high performance liquid 
chromatography time-of-flight (HPLC-TOF), Fourier transform 
infrared spectroscopy attenuated total reflectance (FTIR-ATR) 
and nuclear magnetic resonance (NMR) (Slovenian National 
Forensic Laboratory, 2016).
The implementation of chromatographic techniques, infrared 
and nuclear magnetic resonance spectrometry allow 
unambiguous differentiation between 2- and 
3-furanylfentanyl. As of January 2017, the detection of 
3-furanylfentanyl in Europe has not been reported to the 
EMCDDA.
FIGURE 1
Molecular structure, molecular formula, and molecular mass of furanylfentanyl. Information on fentanyl is provided for 
comparison.
furanylfentanyl fentanyl
Molecular formula C24H26N2O2 C22H28N2O
Molecular mass 374.48 336.48
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It is possible that immunoassays for fentanyl may not 
distinguish between furanylfentanyl and fentanyl due to the 
structural similarity between the two substances (US DEA, 
2016b). Identification of furanylfentanyl therefore would 
require further confirmatory analysis, such as mass 
spectrometry (US DEA, 2016b). Similarly, furanylfentanyl is 
not expected to give a positive response to tests developed 
for morphine-type opioids. There is no information on the 
reaction of furanylfentanyl to presumptive colour tests.
 3.2  Information on the frequency, circumstances 
and/or quantities in which a new psychoactive 
substance is encountered, and information on 
the means and methods of manufacture of the 
new psychoactive substance (Article 5.2(b) of 
the Council Decision)
The data reported to Europol discussed in section 3.2.1 may 
overlap with the data reported to the EMCDDA discussed in 
section 3.2.2.
3.2.1 Information provided to Europol
Europol received replies from 19 Member States (Austria, 
Belgium, Croatia, Cyprus, Czech Republic, Denmark, Estonia, 
Finland, Germany, Greece, Hungary, Ireland, Italy, Latvia, 
Lithuania, Luxembourg, Slovenia, Spain and Sweden) and 
Norway.
Nine countries reported that they have no available 
information on furanylfentanyl (Belgium, Croatia, Greece, 
Hungary, Ireland, Italy, Latvia, Lithuania and Spain).
Eleven countries provided information on furanylfentanyl 
(Austria, Cyprus, Czech Republic, Denmark, Estonia, Finland, 
Germany, Luxembourg, Slovenia, Sweden and Norway).
The United States also provided information to Europol on 
furanylfentanyl seizures.
The level of production
No information was received in relation to the production of 
furanylfentanyl.
Sweden reported that furanylfentanyl is ordered in powder 
form from China and then sent to Sweden, either directly or 
via other EU Member States. Further handling is performed by 
persons involved in the sale, for example converting it to liquid 
form and placing it into unmarked spray bottles of different 
colours ordered from China (as documented in the Joint 
Report on acryloylfentanyl) (EMCDDA, 2016). According to 
Swedish authorities, there are a small number of people who 
are involved in the trafficking of furanylfentanyl in Sweden. In 
general, the same manufacturing and supply chains that deal 
with other fentanil derivatives apply to furanylfentanyl. 
Sweden also reported that one of the biggest on-line vendors, 
thesmack.biz, offered furanylfentanyl for sale but in most 
cases the products contained fentanyl instead.
The level of distribution
A total of 32 seizures were reported by 9 Member States 
(Austria, Cyprus, Czech Republic, Denmark, Estonia, Finland, 
Germany, Luxembourg and Sweden).
Austria
Austria reported 2 seizures, 0.4 grams of white powder and 
15.9 ml of colourless liquid ordered from the internet (origin 
unknown).
Cyprus
Cyprus reported 1 seizure which occurred in 2016. In the 
seizure, 0.87 grams of furanylfentanyl and 0.34 grams of 
butyrylfentanyl were detected.
Czech Republic
Czech Republic reported 1 seizure of furanylfentanyl but 
without additional information. A photo showing how the 
substance was packaged was provided (Annex 2). No other 
information was provided.
Denmark
Denmark reported 1 small seizure of furanylfentanyl, which 
occurred in November 2016. No other details were provided.
Estonia
Estonia reported 10 seizures of furanylfentanyl. All the 
seizures were in powder form, and most of them were under 1 
gram each. The largest seizure was 50 grams, which arrived in 
Estonia from Poland en-route from China in a postal parcel.
Finland
Finland reported 4 seizures of furanylfentanyl by Customs 
amounting to 6.8 grams.
Germany
Germany reported 12 seizures in 2016, ranging from 1.8 to 
74.3 grams. In total, approximately 200 grams of 
furanylfentanyl were seized. In 4 cases China was indicated as 
the country of origin. In the remaining seizures, the country of 
origin is unknown.
Luxembourg
Luxembourg reported 1 seizure of 2.9 grams seized as white 
powder, in a postal parcel sent from China which was destined 
for the Luxembourg market.
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Sweden
Sweden did not provide details on the seizures. These were 
reported to the EMCDDA via the Swedish National Focal Point 
(section 3.2.2).
The level of trafficking
Information related to trafficking routes is limited to the 
seizures reported above. In all cases where the country of 
origin was known, China was indicated (Estonia, Germany, 
Luxembourg and Sweden).
Sweden reported that furanylfentanyl was ordered in powder 
form from China and then sent to Sweden, either directly or in 
transit via other EU Member States.
In addition, Estonia indicated that furanylfentanyl is supplied 
to Estonia primarily from the Czech Republic and Poland.
Additional information provided by Germany, Norway 
and Slovenia
Germany also reported 5 deaths associated with 
furanylfentanyl. These deaths occurred between February and 
June 2016. In 4 out of the 5 cases, post-mortem examinations 
confirmed that furanylfentanyl was consumed in combination 
with other substances.
Norway reported a death case associated with Xanax, which 
most likely contained furanylfentanyl. The investigation 
confirmed that the deceased injected ‘liquid Xanax’ prior to 
his death. The “liquid Xanax” was identified in a small bottle 
(Annex 2). The investigation is ongoing.
Slovenia reported a collected sample of furanylfentanyl 
(section 3.2.2 and Annex 2).
Additional information provided by the United States
The United States reported that no laboratories synthesising 
furanylfentanyl have been identified and there are no 
indications that the substance is produced within the country. 
Although there is limited information available on the 
substance, it appears that furanylfentanyl is produced in 
China, along with a variety of other fentanyl analogues, and 
then it is distributed to opioid users in the United States 
possibly facilitated by Mexican traffickers. Furanylfentanyl is 
distributed to opioid users mixed with or sold as heroin, or 
pressed into counterfeit opioid prescription pills. There is also 
anecdotal reporting of its availability as a nasal spray. 
The producers make furanylfentanyl available for purchase 
online, on both the surface internet and the darknet and also 
through ‘illicit chemical brokers’. According to a recent US 
Drug Enforcement Agency (US DEA) report, an illicit source-
of-supply was selling a kilogram of furanylfentanyl for 
approximately $5,500. The DEA has not identified any 
elaborate money laundering schemes being used in 
furtherance of furanylfentanyl (or other fentanils) trafficking. 
International money remittance services are used to send 
funds to foreign sources-of-supply and to a lesser extent 
Bitcoins are used for fentanyl purchases via darkweb sites.
The US reported that furanylfentanyl has been identified in 
laboratory submissions across the country. Most submissions 
were reported in the Northeast region of the United States and 
were at the gram scale. A seizure of 3,500 counterfeit 
OxyContin tablets containing furanylfentanyl was reported in 
Connecticut in August 2016. In Tennessee a parcel seized in 
August 2016 which had originated in China contained 2.8 kg 
and 2.75 kg of furanylfentanyl.
According to the US National Forensic Laboratory Information 
System (NFLIS), which includes data from state and local 
laboratories, 494 samples containing furanylfentanyl were 
analysed as of 2 November 2016. The first NFLIS report of 
furanylfentanyl was in December 2015 in the State of Oregon. 
According to the DEA laboratory reporting system, DEA 
laboratories have encountered 113 samples containing 
furanylfentanyl as of 2 November 2016. The first submission to 
a DEA laboratory was in February 2016. The total number of 
seizures from both systems amounted to 607.
3.2.2 Information provided to the EMCDDA
The EMCDDA received responses from the 28 Member States, 
as well as from Turkey and Norway. Of these, 15 Member 
States (Austria, Belgium, Cyprus, Denmark, Estonia, Finland, 
France, Germany, Hungary, Luxembourg, Poland, Slovenia, 
Spain, Sweden and the United Kingdom) and Norway reported 
detections of furanylfentanyl (9). Images of the seizures and 
collected samples reported to the EMCDDA are provided in 
Annex 1.
It is important to note that detections of furanylfentanyl may 
be under-reported since the substance is not routinely 
screened for. Two Member States (Finland and Sweden) 
reported that furanylfentanyl is part of routine screening. 
Slovenia reported that they routinely screen for furanylfentanyl 
in seized and collected samples.
(9) ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities (police, 
customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring 
and research purposes. Biological samples are those from human body fluids 
(urine, blood, etc.) and/or specimens (tissues, hair, etc.). 
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Seizures
In total, 113 seizures (10) have been reported to the EMCDDA 
by 12 Member States: Austria (3 seizures), Belgium (3), 
Cyprus (1), Denmark (1), Estonia (10), Finland (18), Germany 
(14), Hungary (1), Luxembourg (1), Poland (17), Sweden (38) 
and the United Kingdom (6). The majority of seizures were 
made in 2016 by Police or Customs.
The majority of furanylfentanyl seizures in Sweden were in 
liquid form, detected in nasal spray bottles. Most of the 
seizures reported by Finland were sent from Poland via 
airmail.
Seizures of furanylfentanyl included:
 ¡ 17 seizures of liquids in Austria, Finland and Sweden, 
amounting to a total of 1421 mL. Seizures in Austria and 
Sweden were as ‘nasal spray bottles’. The largest single 
seizure of furanylfentanyl in liquid form was 974.5 mL 
seized by Police in Finland;
 ¡ 3 seizures of tablets in Sweden, amounting to 45 tablets;
 ¡ 76 seizures of powder amounting to 720.35 grams (Austria, 
Belgium, Cyprus, Denmark, Estonia, Finland, Germany, 
Hungary, Luxembourg, Sweden and the United Kingdom). 
The largest single seizure of furanylfentanyl in powder form 
was 50.08 grams seized by Estonian Customs;
 ¡ 12 seizures of herbal material amounting to 5.75 grams in 
Poland;
 ¡ 5 seizures of furanylfentanyl in Poland where the physical 
form was not reported.
Other substances detected in seized powder samples include: 
4-fluoroisobutyrylfentanyl (4F-iBF); ortho-fluorofentanyl, 
cocaine and mannitol; diamorphine; inositol; lactose; mannitol; 
and paracetamol and caffeine.
No quantitative information on purity was provided.
Poland reported a case from Krakow, in 2013, regarding the 
production of new psychoactive substances (NPS) including 
the fentanils 4-fluoro-butyrfentanyl, butyrfentanyl and 
furanylfentanyl. Preliminary analysis by LC-MS/MS revealed 
the presence of furanylfentanyl and traces of 4-ANPP (11). 
NMR was not performed.
(10) Many ‘seizures’ relate to individual cases, however, some data provided to the 
EMCDDA are aggregated at the country level. Data is drawn from the Joint 
Report Questionnaires and data provided in the bi-annual data gathering (EU 
EWS Progress Reports and Final Reports) and from individual EMCDDA–Europol 
Reporting forms submitted to the EMCDDA on an ad hoc basis.
(11) 4-Anilino-N-phenethylpiperidine. 
Collected samples
A total of 11 collected samples were reported by 3 Member 
States (France (4), Slovenia (1) and Spain (6)). The majority of 
the samples were in powder form, two samples were in liquid 
form, and sold as a nasal spray and as an e-liquid (France).
 ¡ the 4 samples collected by France were purchased from 
vendors on darknet market places: 1 of the samples was 
purchased as U-47700 and another sample came from 
China. The two samples in liquid form also contained 
glycerol (Annex 1).
 ¡ Slovenia reported a collected sample containing 
furanylfentanyl which was test-purchased from the internet 
(Annex 1).
 ¡ The samples reported by Spain were collected from users. 
The samples were sold as fentanyl (3 samples), carfentanil 
(1) and methadone (1).
Biological samples
A total of 20 biological samples were reported in which 
furanylfentanyl was analytically detected. These were reported 
by four Member States (Estonia, 4; Germany, 4; Sweden, 10; 
United Kingdom, 1) and Norway (1).
All 20 samples were taken from individuals who suffered 
serious adverse events (section 3.4.1).
 3.3  Information on the involvement of organised 
crime in the manufacture or trafficking of the new 
psychoactive substance (Article 5.2(c) of the 
Council Decision)
No information concerning the involvement of organised crime 
in the manufacture and/or trafficking of the furanylfentanyl 
was provided.
In all cases where the origin was known, China was indicated 
as the country of origin (Estonia, Germany, Luxembourg and 
Sweden).
Estonia reported that the level of trafficking of furanylfentanyl 
is low after the substance was controlled nationally. Suppliers 
have been trying to replace fentanyl in drug market, 
unsuccessfully. Furanylfentanyl seized in Estonia was 
destined for domestic market and there is no available 
information on further transit and/or export.
Sweden reported that furanylfentanyl is ordered in powder 
form from China and then sent to Sweden, either directly or 
via other EU Member States. According to Swedish 
authorities, there are a small number of people who are 
involved in the trafficking of furanylfentanyl in Sweden. In 
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general, the same manufacturing and supply chains that deal 
with other fentanyl derivatives apply to furanylfentanyl.
Money laundering aspects
No information was received on money laundering in 
connection with the production and/or trafficking of 
furanylfentanyl.
Swedish authorities indicate that sales of fentanyl and 
fentanyl analogues via the internet generate large profits, even 
though the Swedish market for fentanyl is relatively limited.
Violence in connection with production, wholesale and 
distribution
No information was received on incidents of violence in 
connection with the production, wholesale and/or trafficking 
of furanylfentanyl.
Estonia reported that there is no information regarding 
violence related specifically to furanylfentanyl, outside what 
would be considered ‘normal’ violence associated with the 
trafficking of illicit drugs.
  3.4  A first indication of the risks associated with the 
new psychoactive substance, including the health 
and social risks, and of the characteristics of 
users — Article 5.2(d) of the Council Decision 
3.4.1  Serious adverse events reported to the 
EMCDDA
A total of 29 serious adverse events (12) associated with 
furanylfentanyl were reported by four Member States (Estonia, 
Germany, Sweden, United Kingdom) and Norway. They 
comprised 10 acute intoxications and 19 deaths.
Acute intoxications
A total of 10 acute intoxications associated with 
furanylfentanyl were reported by three Member States 
(Germany, 4; Sweden, 5; United Kingdom, 1). Of these, 1 was 
classed as a confirmed case (13), 1 as a probable case, and 8 
(12) Serious adverse event means any adverse event, whether analytically 
confirmed or not, that is associated with the consumption of a new psychoactive 
substance in a human that: results in death; is life-threatening; requires intensive 
treatment in an emergency room and/or requires hospitalisation; results 
in persistent or significant disability or incapacity; results in substance 
dependency or substance abuse; consists of a congenital anomaly or birth 
defect; or is an important medical event that may not be immediately life-
threatening or result in death or hospitalisation but may jeopardise the patient or 
may require intervention to prevent one of the other outcomes listed above. 
Examples of such events are: convulsions that do not result in hospitalisation.
(13) This case has been published in the literature (see Helander et al., 2016). 
as suspected cases (14). They occurred between November 
2015 and September 2016.
Demographics
Of the 10 intoxications, 8 were male and 2 were female. The 
mean age of the males was 23 (median 22) and ranged from 
15 to 32 years (data available for 5 cases); the females were 
aged 20 and 32 years.
Substances analytically identified
Analytical confirmation was limited to the confirmed case and 
probable case.
In the confirmed case, furanylfentanyl, ethanol, 5-EAPB, and 
MDPHP were identified in the biological samples taken from 
the patient.
In the probable case, furanylfentanyl and mannitol were 
identified in a sample of the drug that was snorted by the 
patient.
Clinical features
The clinical features of the intoxications were generally 
consistent with µ-opioid agonist toxicity (data available for 7 
cases). They included unconsciousness (3 cases) or reduced 
level of consciousness (2), respiratory arrest or depression (2) 
and miosis (1). In one case tachycardia and high body 
temperature were also reported.
It is important to note that in the confirmed case, ethanol and 
stimulants were also identified in the biological sample from 
the patient. In addition, in 2 of the suspected cases the 
patients reported taking either other central nervous system 
depressants or stimulants. Information on exposure to other 
substances was either unknown or not reported in the 
remaining 7 cases.
Administration and response to naloxone
In 3 cases (15), naloxone was administered as an antidote. In 2 
of these cases, the patients were unconscious and regained 
consciousness following administration of naloxone. No 
further details were reported in third case.
(14) For the purposes of this report the following definitions are used. Confirmed 
case means that information on exposure to furanylfentanyl is available from 
analytical confirmation in one or more biological samples taken from a patient. 
Probable case means that information on exposure was only available from the 
analytical confirmation of furanylfentanyl in a drug sample and that there is 
a reasonable probability that the patient was exposed to that drug sample. 
Suspected case means that information on exposure is typically limited to the 
name of the substance that the patient believes that they have consumed and/or 
from packages containing the drugs that the patient is thought to have 
consumed. As a result, information on the features of the intoxication from 
probable and suspected cases should be interpreted with caution.
(15) Including the confirmed case.
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The information was either unknown or not reported in the 
remaining 7 cases.
Seriousness and outcome
In 5 cases it was reported that treatment in an emergency 
room/hospital was required (16). The information was either 
unknown or not reported in the remaining 5 cases.
In 5 cases the seriousness of the intoxication was classified as 
life-threatening (3 cases) or severe (2). In 1 case the 
seriousness was classed as not life-threatening. The 
information was either unknown or not reported in the 
remaining 4 cases.
In 2 cases it was reported that the patient recovered. The 
information was either unknown or not reported in the 8 
remaining cases.
Route of administration
In 1 case a solution of furanylfentanyl was administered 
nasally (by nasal spray) and by intramuscular injection (17). In 
1 case furanylfentanyl was snorted as a powder (18). In 2 
cases furanylfentanyl was administered nasally. In 2 cases 
furanylfentanyl was administered orally. The information was 
either unknown or not reported in the 4 remaining cases.
Name of the substance/product used
In 8 cases the patient was reported to have taken 
‘furanylfentanyl’. The information was either unknown or not 
reported in the 2 remaining cases.
Source of the substance
In 2 cases furanylfentanyl was reported to have been sourced 
from the internet (19). The information was either unknown or 
not reported in the 8 remaining cases.
Physical form
In 3 cases the physical form of furanylfentanyl used by the 
patients was reported to have either been a solution in a nasal 
spray (2 cases) or a powder (1 case) (20). The information was 
either unknown or not reported in the remaining 7 cases.
Amount or dose administered
In 2 cases (21) the amount of furanylfentanyl used was 
reported as 5 mg nasally (1 case) and 50 mg orally (1 case). 
The information was either unknown or not reported in the 
remaining 8 cases.
(16) Including the confirmed and probable case.
(17) The confirmed case.
(18) The probable case.
(19) The probable case and a suspected case.
(20) The probable case.
(21) Both suspected cases.
Deaths
At total of 19 deaths associated with furanylfentanyl were 
reported by four Member States (Estonia, 4; Germany, 4; 
Sweden, 9; United Kingdom, 1) and Norway (1). They occurred 
between November 2015 and October 2016 (22). 
Furanylfentanyl was analytically confirmed in biological 
samples from all 19 cases.
Demographics
Of the 15 deaths for which data was available, 13 were male 
(87%) and 2 were female (13%). The mean age of the males 
was 29.9 years (median 27) and ranged from 25 to 38; the two 
females were aged 33 and 48.
Number of deaths by year
Two deaths occurred in 2015 (November) and 17 deaths 
occurred in 2016 (January to October (23).
Circumstances of death
In 15 cases it was reported that the decedents were found 
dead. This included deaths that occurred at home (6 cases) 
and outside (1 case). In 2 cases it was reported that drug 
paraphernalia and powders were found at the scene of death.
The information was either unknown or not reported in the 
remaining 4 cases.
Cause of death
In 12 cases the cause of death was reported. Briefly:
 ¡ In 6 cases the cause of death was reported either as 
overdose or intoxication with furanylfentanyl (5 cases) or 
intoxication with furanylfentanyl in combination with 
pregabalin (1 case).
 ¡ In 3 cases the cause of death was reported as overdose of 
narcotics (2 cases) or intoxication with drugs and narcotics 
(1 case).
 ¡ In 3 cases it was reported that furanylfentanyl in 
combination with other substances likely played a role in 
the death.
The cause of death was either not yet available or not reported 
for the remaining 7 cases.
Substances analytically identified
Information on the substances identified in biological samples 
was available for 18 deaths. This data was incomplete in 3 of 
these cases.
(22) The month of death was not reported in one case that occurred in 2016.
(23) At least 16 of the deaths occurred between January and October 2016. In the 
remaining case that occurred in 2016 the month of death was not reported.
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In 3 cases furanylfentanyl was the only substance detected; in 
2 of these cases the cause of death was reported as overdose 
or intoxication with furanylfentanyl; in the remaining case the 
cause of death was not yet available.
In 15 cases other substances were detected with 
furanylfentanyl. In 9 cases this included other opioids (such as 
fentanyl in 7 cases). Other central nervous system (CNS) 
depressants such as benzodiazepines, ethanol, and 
gabapentinoids were detected in some of the deaths. In 
addition, THC, amphetamine, cocaine and MDMA were also 
detected in some cases.
Route of administration
Information on the route of administration was reported for 2 
deaths. In 1 case furanylfentanyl was snorted as a powder and 
in 1 case it was injected intravenously. The information was 
either unknown or not reported in the remaining 17 cases.
Source of the substance
No information was reported on where the decedents had 
sourced the furanylfentanyl.
Amount or dose administered
No information was reported on the amount of furanylfentanyl 
administered by the decedents.
Name of the substance/product used
In 1 case the decedent was reported to have taken ‘Fu-F, 
Furanyl-Fentanyl’. In another case furanylfentanyl may have 
been in a product called ‘liquid Xanax’ (section 3.2.1 and 
Annex 2). The information was either unknown or not reported 
in the remaining 17 cases.
3.4.2  Serious adverse events identified in open 
source information
In the United States, 128 deaths associated with 
furanylfentanyl that occurred between 2015 and July 2016 
have been reported. The deaths occurred in Illinois, Maryland, 
New Jersey, North Carolina, and Ohio (US DEA, 2016b) (24).
On the basis of these deaths, as well as other information, 
furanylfentanyl was temporarily scheduled into schedule I of 
the Controlled Substances Act (US DEA-DoJ, 2016).
In British Columbia, Canada, a hospital emergency 
department identified a large increase in suspected opioid 
overdose events over a four-day period in July 2016. During 
(24) In addition, a case series of 8 deaths from the United States where 
furanylfentanyl was analytically detected has been published (Mohr et al., 2016). 
This case series may be a subset of cases from the cases reported by the United 
States Drug Enforcement Administration (US DEA, 2016b).
this time they treated 43 patients with suspected opioid 
overdose. Just over 50% of the patients lost consciousness 
after smoking what they believed to have been crack cocaine. 
Samples of the drugs used by the patients were analysed and 
found to contain furanylfentanyl and cocaine. While most of 
the patients were treated and discharged within a few hours, 6 
of the patients were admitted to the hospital; including 3 who 
were transferred to the intensive care unit, 1 of whom died 
(Klar et al., 2016).
3.4.3 Pharmacology
Overview
Published data on the pharmacology of furanylfentanyl are 
limited to in vitro and in vivo animal studies. These data 
suggest that furanylfentanyl is a selective and potent µ-opioid 
receptor agonist with a pharmacology that is broadly 
comparable to fentanyl.
Additional research is required in order to have a more 
detailed understanding of the mode and mechanism of action 
of furanylfentanyl and its metabolites.
Pharmacodynamics
In vitro data
Pharmacological data on furanylfentanyl have been published 
recently by the United States Drug Enforcement 
Administration (US DEA, 2016b).
The binding affinity (K
i
) (25) of furanylfentanyl to opioid 
receptors was evaluated using an in vitro preparation of 
transfected Chinese hamster ovary cells expressing human 
δ and κ opioid receptors and rat µ opioid receptors (US DEA, 
2016b). Furanylfentanyl showed selectivity for the µ opioid 
receptor (K
i
 = 0.0279 ± 0.0080 nM) compared to the δ (K
i
 = 54 
± 15 nM) and κ (K
i
 = 59.2 ± 6.4 nM) opioid receptors when 
[3H]-DAMGO was used as a radioligand. This experiment 
indicates that furanylfentanyl is a selective ligand for the 
µ-opioid receptor.
An in vitro functional assay found that furanylfentanyl (EC
50 
= 
2.52 ± 0.46 nM) has µ-opioid receptor agonist activity, similar 
to morphine (EC
50
 = 31.0 ± 8.2 nM) and fentanyl (EC
50
 = 17.9 ± 
4.3 nM) (Table 1).
(25) K
i 
is defined as the equilibrium dissociation constant of the ligand determined 
by inhibition studies. 
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TABLE 1
Potency of furanylfentanyl, fentanyl and morphine at the µ-, 
κ- and δ-opioid receptors assessed by an in vitro functional 
assay ([35S]GTPγS binding) measured by the EC
50
 (nM) (US 
DEA, 2016).
Compound µ-receptor κ-receptor δ-receptor
Furanylfentanyl 2.52 ± 0.46 60 ± 25 >10 µM
Fentanyl 17.9 ± 4.3 362 ± 47 1190 ± 140
Morphine 31.0 ± 8.2 83 ± 23 870 ± 140
Animal studies
Furanylfentanyl was found to have analgesic activity when 
administered intravenously with an ED
50
 (26) of 0.02 mg/kg 
using the mouse hot plate test (Huang et al., 1986). 
Comparative data for morphine and fentanyl were not 
reported.
Pharmacokinetics
No studies have investigated the pharmacokinetics of 
furanylfentanyl. Based on its structural similarity to fentanyl, it 
is expected to cross the blood-brain barrier, and diffuse into 
adipose and other tissues.
Abuse liability and dependence potential
No specific data are available on the abuse liability and 
dependence potential of furanylfentanyl. However, it is well 
documented that µ-opioid receptor agonists such as fentanyl 
have an abuse liability and dependence potential.
Limited information from self-reported user experiences 
suggests that furanylfentanyl may have an abuse liability and 
dependence potential.
3.4.4 Toxicology
Non-clinical data
There are no data from non-clinical studies on the acute or 
chronic toxicity of furanylfentanyl.
Human data
Based on the available information, it appears that poisoning 
with furanylfentanyl may be broadly similar to other potent 
fentanils and may include a rapid loss of consciousness and 
profound respiratory depression.
It appears that poisoning with furanylfentanyl can be reversed 
by administration of naloxone. Similar to poisoning with other 
fentanils, it has been reported that multiple doses may be 
required to reverse the effects (Klar et al., 2016).
(26) ED
50
 is the dose at which 50% of test animals meet the criteria for the 
analgesic response.
3.4.5 Characteristics of users
Data on the characteristics of users of furanylfentanyl is 
limited to information provided from serious adverse events 
(section 3.4.1 and section 3.4.2) and self-reported user 
experiences from user websites.
Data from user websites should be interpreted with caution. 
This is because it is not possible to confirm the specific 
substance(s) used nor the strength, purity, dose/amount used. 
In addition, information provided on such sites may not 
necessarily be representative of other users of furanylfentanyl 
and should be regarded as illustrative only.
Route of administration, drug regimen
Routes of administration for furanylfentanyl includes oral (as 
a powder or tablet), nasal (using nasal sprays or by insufflation 
of a powder) and by injection (intravenous and intramuscular). 
These routes are similar to those reported with other fentanils. 
Of note is the apparent popularity of using ready-to-use or 
home-made nasal sprays containing solutions for the 
administration of furanylfentanyl. This finding extends to the 
use of other fentanils that have appeared in Europe in the past 
few years.
User websites also mention other routes of administration 
such as vaping solutions of furanylfentanyl using e-cigarettes. 
E-liquids containing furanylfentanyl have been reported by 
France in collected samples test-purchased from vendors on 
darknet marketplaces (section 3.2.2).
Poland reported several seizures of branded ‘legal-high’-type 
products which contained furanylfentanyl in herbal material. It 
is not known if these products were intended to be smoked or 
taken orally (section 3.2.2).
User groups
The available data suggests that users of furanylfentanyl 
include high risk drug users and psychonauts.
Some individuals who use furanylfentanyl are polydrug users. 
This includes the use of other CNS depressants such as 
opioids, benzodiazepines, and gabapentinoids.
Settings of use
The available data suggests that one common setting of use 
for furanylfentanyl is the home. This finding is similar to the use 
of other fentanils and narcotic-analgesic opioids in general.
Dose, re-dosing, drug regimens
The available data does not allow the identification of 
common/typical doses of furanylfentanyl regardless of route.
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There are no studies which indicate the doses required to 
produce subjective effects of furanylfentanyl in humans.
Subjective, psychological, and behavioural effects
There are no studies assessing the psychological and/or 
behavioural effects of furanylfentanyl in humans. The available 
data suggests that the effects of furanylfentanyl resemble 
those of other narcotic-analgesic opioids such as fentanyl.
Effect on ability to operate machinery and drive
Based on the available data it should be assumed that the 
acute behavioural effects of furanylfentanyl on operating 
machinery and driving are similar to those caused by other 
opioid narcotic-analgesics such as fentanyl. This includes the 
potential for profound CNS depression.
Availability, supply, price
Online vendors
A structured search by the EMCDDA of online vendors (27) of 
furanylfentanyl on the surface web (28) was conducted in 
December 2016. The search identified 46 vendors that 
appeared to be based in, and/or claim to have presence in China 
(n = 27 sites), the United States (n = 5 sites), Hong Kong (n = 3 
sites), India (n = 1 site), South Korea (n = 1 site), Ukraine (n = 1 
site) and the United Kingdom (n = 1 site). For the remaining 7 
vendors, there was no apparent location mentioned.
Twenty two of the sites provided quantities and prices for 
furanylfentanyl upon request. The remaining 24 sites listed 
quantities and prices. In brief:
 ¡ Furanylfentanyl was usually offered in powder form. 
Typically it was listed as a ‘research chemical, not fit for 
human consumption’;
 ¡ One site offered furanylfentanyl as a ready-to-use nasal 
spray and also ‘o-liquid’ intended for vaping in e-cigarettes. 
This site also offered furanylfentanyl in powder form mixed 
with either mannitol (ratio of 1:10) or caffeine (ratio of 1:25);
 ¡ The minimum quantity offered was 1 g (n = 6 sites) with an 
mean price of EUR 54;
 ¡ The mean price for 10 g was EUR 193 (n = 6 sites), 100 
g was EUR 924 (n =5 sites) and 1 kg EUR 5299 (n = 4 sites);
 ¡ The maximum quantity offered was 5 kg with a price of EUR 
29,467 (n = 1 site).
(27) This includes vendors that appear to be consumer-orientated as well as 
vendors which appear to be manufacturers and/or wholesalers (for example on 
B2B sites). It excludes those selling furanylfentanyl through online classified 
advertisements, social media, and user websites.
(28) The search of online vendors of furanylfentanyl was performed on 
19/12/2016 using the search strings: ‘buy furanylfentanyl’ (searches in English, 
Swedish and Danish, including variations in spelling). The first 100 results were 
recorded and the sites reviewed. Each identified vendor site was then scored for 
information on geographical location, quantities and prices, and substance 
marketing.
Prices were listed in United States Dollars on all 24 sites (29).
In 4 collected samples reported by France, the furanylfentanyl 
was purchased from vendors on darknet marketplaces.
Prevalence of use
No general population surveys or targeted surveys were 
identified that had examined the prevalence of use of 
furanylfentanyl.
In addition, it is possible that some users may not be aware 
that they are taking furanylfentanyl. In Europe, furanylfentanyl 
has been sold as other opioids (including methadone). It has 
also been detected with heroin in one small seizure. In 
addition, it has also been detected in branded legal high 
products. In Canada, furanylfentanyl in crack cocaine was 
responsible for an outbreak of serious poisonings during July 
2016. Users who are unaware that they are taking 
furanylfentanyl could be at increased risk of serious poisoning.
 3.5  Information on whether or not the new substance 
is currently under assessment, or has been under 
assessment, by the UN system (Article 5.2(e) of 
the Council Decision)
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 
1961 and the Convention on Psychotropic Substances, 1971.
On 23 November 2016, the World Health Organization 
informed the EMCDDA that furanylfentanyl is currently not 
under assessment and has not been under assessment by the 
UN system.
 3.6  The date of notification on the Reporting Form of 
the new psychoactive substance to the EMCDDA 
or to Europol (Article 5.2(f) of the Council 
Decision)
The first official EMCDDA–Europol notification of 
furanylfentanyl dates from 3 November 2015 from the Finnish 
National Focal Point. The Reporting Form details the seizure of 
furanylfentanyl in 0.2 grams of pale brown powder in incoming 
mail from Poland, seized by Finnish Customs on 29 June 
(29) Prices listed in USD were converted to EUR according to the XE Currency 
Converter from the 11/01/2017 (USD 1 = EUR 0.95). The prices were then 
rounded up to the nearest EUR.
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2015. The identification and analytical characterisation by 
GC-MS, LC-MS and NMR was conducted by the Swedish 
National Forensic Centre.
Furanylfentanyl was added to the list of new psychoactive 
substances monitored by the EMCDDA and Europol through 
the European Union Early Warning System. A profile of the 
substance was created on the European Database on New 
Drugs (EDND). Since then, analytical details and other 
information, including a public health alert, have been 
exchanged between the EMCDDA, Europol, and the Member 
States, Turkey, and Norway, on an ad hoc basis; the European 
Commission and the EMA have been kept duly informed.
It is important to note that it appears that furanylfentanyl was 
first detected in 2013, as evidenced by the report of 
a detection of furanylfentanyl in a sample seized during a case 
involving the production of NPS in Poland (section 3.2.2). 
However, it appears that, where known, furanylfentanyl has 
been sourced outside the EU.
 3.7  Information on whether or not the new 
psychoactive substance is already subject to 
control measures at national level in a Member 
State (Article 5.2(g) of the Council Decision)
Seven Member States (Cyprus, Denmark, Estonia, Finland, 
Latvia, Lithuania and the United Kingdom) and Turkey 
reported that furanylfentanyl is controlled under drug control 
legislation.
 ¡ In Cyprus, furanylfentanyl is controlled within the context of 
a generic clause which addresses fentanyl chemical 
groups.
 ¡ In Denmark, it is included in the amendment of the 
Executive Order on Euphoriant Substances which entered 
into force on 24 November 2016.
 ¡ In Estonia furanylfentanyl is controlled by way of generic 
definition.
 ¡ In Finland, the substance is controlled as a narcotic since 1 
April 2016.
 ¡ In Latvia, furanylfentanyl is included in the Cabinet 
Regulation N 847 ‘Regulations regarding Narcotic 
Substances, Psychotropic Substances and Precursors to 
be Controlled in Latvia’ and the law ‘On the Procedures for 
the Coming into force and Application of the Criminal Law’.
 ¡ In Lithuania, furanylfentanyl is subjected to control 
measures by The Republic of Lithuania Minister of Health 
Order No V-1511 (28/12/2015) ‘On the amendment of the 
Ministry of Health of the Republic of Lithuania Order No. 5 
of 6 January 2000’.
 ¡ In the United Kingdom, furanylfentanyl is controlled under 
the Misuse of Drugs Act 1971 by way of a generic definition.
 ¡ In Turkey, furanylfentanyl is under control of Drug Law on 
Drugs numbered 2313 (Official Gazette 29790 of 3 August 
2016).
Three Member States (Austria, Hungary and Poland) reported 
that furanylfentanyl is controlled under specific new 
psychoactive substances control legislation.
 ¡ In Austria, furanylfentanyl is covered by the Austrian Act on 
New Psychoactive substances.
 ¡ In Hungary, furanylfentanyl is listed in the ministerial decree 
No. 55/2014 (XII.3.) EMMI since 25 December 2016.
 ¡ In Poland, furanylfentanyl is controlled according to the 
general definition of the ‘substitute drug’. Pursuant to 
Article 44b of the Act on counteracting drug addiction and 
Article 27c of the Act of 14 March 1985 on State Sanitary 
Inspection (Journal of Laws ‘Dz. U.’ of 2011, No. 212, item 
1263), it is prohibited to manufacture and introduce 
substitute drugs to trade.
Germany reported that it is not known whether furanylfentanyl 
may be controlled under specific NPS control legislation (30).
One Member State (Sweden) and Norway reported that 
furanylfentanyl is controlled under other types of legislation:
 ¡ In Sweden, furanylfentanyl is regulated in the Act on the 
Prohibition of Certain Goods Dangerous to Health (SFS 
1999:42), as of 26 January 2016.
 ¡ In Norway, the import of and trade in furanylfentanyl is 
controlled by the Medicinal Products Legislation.
Sixteen Member States (Belgium, Bulgaria, Croatia, Czech 
Republic (31), France, Greece, Ireland, Italy, Luxembourg, 
Malta, the Netherlands, Portugal, Romania, Slovakia, Slovenia 
(32) and Spain) reported that furanylfentanyl is not subject to 
control measures at the national level.
(30) The substance was discussed in the bi-annual expert committee in 
December 2016 but no official decision had been published at the time of writing 
the report.
(31) The Czech Republic reported that it has been proposed that the substance is 
included in the amendment of Government Regulation No. 463/2013 Coll. It is 
expected that the amendment will come into force in early 2017. 
(32) Slovenia reported that the proposal for regulation of furanylfentanyl is in the 
legislative procedure. 
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 3.8  Further information (Article 5.2(h) of the Council 
Decision)
3.8.1  The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States, Turkey, or 
Norway, about the chemical precursors or manufacturing 
methods used to make the furanylfentanyl which has been 
detected within Europe.
The synthesis of furanylfentanyl was first described in a 1986 
patent (Huang et al., 1986). The published synthetic method 
for furanylfentanyl describes the addition of 2-furoyl chloride 
to the precursor 4-ANPP (33,34).
The detection of traces of 4-ANPP in a seized sample of 
furanylfentanyl in Poland and the availability of 4-ANPP on the 
chemicals market suggest it may have been used as 
a precursor in the manufacture of furanylfentanyl. The seized 
furanylfentanyl sample was from a case in Krakow that 
involved the production of a number of different new 
psychoactive substances. Two other fentanyl derivatives, 
4-fluoro-butyrfentanyl and butyrfentanyl, were also detected 
during analysis of seized samples from this case.
The manufacture of furanylfentanyl relies on precursors and 
synthetic methods similar to those used for the manufacture 
of pharmaceutical fentanyl (Casy and Huckstep, 1988; Gupta 
et al., 2013; Zee and Wang, 1980). Therefore the methods 
developed for the synthesis of fentanyl are applicable to the 
synthesis of furanylfentanyl.
Most of the synthetic procedures are straightforward, use 
common laboratory equipment and precursors, and detailed 
recipes are available on the internet (35). While only basic 
knowledge of synthetic chemistry is required, due to the 
potency of fentanils extreme caution is required when carrying 
out the final synthetic step as well as when purifying and 
handling the substance (36). Exposure of the skin and mucous 
membranes to fentanils as well as their inhalation pose 
(33) CAS RN: 21409-26-7. For analytical characterisation, see: http://www.
swgdrug.org/Monographs/4ANPP.pdf. Note that 1-(2-phenylethyl)piperidin-4-
one, or NPP (CAS RN: 39742-60-4), a precursor to 4-ANPP, is also used for the 
manufacture of the bronchodilatory medicine fenspiride.
(34) The synthesis of 4-ANPP from phenethylamine and ethyl (or methyl) acrylate 
is well documented (Beckett et al., 1959; Jończyk et al., 1978; Maryanoff et al., 
1982). For another route, see Valdez et al., 2014.
(35) The detailed description of the most common procedure, referred to as the 
‘Siegfried method’, is readily available on the internet (see, for example, http://
opioids.com/fentanyl/synthesis.html).
(36) Self-educated clandestine chemists commented on the risk while discussing 
the synthesis of fentanyl and its potent 3-methyl and α-methyl homologues 
(comment was posted on 7 May, 2002); available at: https://the-hive.archive.
erowid.org/forum/showflat.pl?Cat=&Number=260275 (Accessed: 6 October 
2016).
a serious risk of accidental poisoning. In addition to exercising 
extreme caution, suitable personal protective equipment as 
well as sufficient stocks of naloxone as an antidote to 
poisoning following accidental exposure should be available 
when handling materials suspected to contain these 
substances (CDCP, 2013; US DEA, 2016a).
The precursors N-phenethyl-4-piperidone (NPP) and 4-ANPP 
are offered from gram to bulk (multikilogram) quantities on the 
internet from dozens of suppliers. For example, prices for the 
immediate precursor 4-ANPP range from USD 75 per 100 
gram to USD 5000 per 1 kg.
Neither NPP nor 4-ANPP are included in Table I or Table II of 
the United Nations Convention against Traffic in Narcotic 
Drugs and Psychotropic Substances, 1988. In June 2010, the 
US Drug Enforcement Administration placed 4-ANPP (named 
ANPP in the regulation) into Schedule II of the Controlled 
Substances Act (US DEA-DoJ, 2010).
In summary, the synthesis of furanylfentanyl has been 
described in the literature. Other routes developed for the 
production of fentanyl may also be used for the manufacture 
of furanylfentanyl. There is no information on the actual 
method(s) used for the production of furanylfentanyl that has 
been detected in Europe to date.
3.8.2  The mode and scope of the established or 
expected use of the new substance
No studies were identified that have examined the mode and 
scope of established or expected use of furanylfentanyl. Given 
the limited information currently available, the relevant 
information has been included in the previous sections.
3.8.3  Other use of the new psychoactive substance 
and the extent of such use, the risks associated 
with this use of the new psychoactive 
substance, including the health and social risks
No information was provided by the Member States, Turkey or 
Norway that indicated that furanylfentanyl had any other use 
apart from in analytical reference materials and scientific 
research.
From the available information, it does not appear that 
furanylfentanyl is used in the manufacture of a medicinal 
product in the European Union. However, the data collection is 
incomplete and some countries indicated that this information 
is not known. It is understood that the collection of such 
information is a challenge in the absence of a database on the 
synthetic route of all medicinal products.
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Eight countries (Austria, Czech Republic, Denmark, Finland, 
Germany, the Netherlands, Spain and the United Kingdom) 
reported that furanylfentanyl is not used to manufacture 
a medicinal product for human use. Twelve countries 
(Belgium, Croatia, Estonia, Greece, Hungary, Iceland, Ireland, 
Italy, Latvia, Norway, Slovakia and Sweden) reported that it 
was unknown if furanylfentanyl is used to manufacture 
a medicinal product for human use.
In addition, the EMA reported that it is not known if 
furanylfentanyl is used in the manufacture of medicinal 
products for human use and which are centrally authorised 
within the European Union.
Nine countries (Austria, Denmark, Finland, France, Greece, 
Latvia, Poland, Slovakia and Spain) provided information that 
furanylfentanyl is not used to manufacture a medicinal 
product for veterinary use. Eleven countries (Belgium, Estonia, 
Germany, Hungary, Iceland, Ireland, the Netherlands, Norway, 
Portugal, Slovenia and Sweden) reported that it was unknown 
if furanylfentanyl is used to manufacture a medicinal product 
for veterinary use.
In addition, the EMA reported that it is not known if 
furanylfentanyl is used in the manufacture of medicinal 
products for veterinary use and which are centrally authorised 
within the European Union.
 4.  Information from the EMA (Article 5.3 
of the Council Decision)
| 4.1 Marketing authorization
Twenty countries (Austria, Belgium, Croatia, Czech Republic, 
Denmark, Estonia, Finland, Germany, Greece, Hungary, 
Iceland, Ireland, Italy, Latvia, the Netherlands, Norway, 
Slovakia, Spain, Sweden and the United Kingdom) reported 
that furanylfentanyl has not been granted a marketing 
authorization as a medicinal product for human use.
Twenty countries (Austria, Belgium, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, 
Latvia, the Netherlands, Norway, Poland, Portugal, Slovakia, 
Slovenia, Spain and Sweden) reported that furanylfentanyl has 
not been granted a marketing authorization as a medicinal 
product for veterinary use.
The EMA also reported that furanylfentanyl has not been 
granted a marketing authorization as a medicinal product for 
neither human nor veterinary use through the centralized 
procedure.
 4.2 Application for a marketing authorization
Twenty countries (Austria, Belgium, Croatia, Czech Republic, 
Denmark, Estonia, Finland, Germany, Greece, Hungary, 
Iceland, Ireland, Italy, Latvia, the Netherlands, Norway, 
Slovakia, Spain, Sweden and the United Kingdom) reported 
that furanylfentanyl is not the subject of an application for 
a marketing authorization as a medicinal product for human 
use.
Twenty countries (Austria, Belgium, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, 
Latvia, the Netherlands, Norway, Poland, Portugal, Slovakia, 
Slovenia, Spain and Sweden) reported that furanylfentanyl is 
not the subject of an application for a marketing authorization 
as a medicinal product for veterinary use.
The EMA also reported that furanylfentanyl is not the subject 
of an application for a marketing authorization for neither 
human nor veterinary use through the centralized procedure.
 4.3 Suspended marketing authorization
Twenty countries (Austria, Belgium, Croatia, Czech Republic, 
Denmark, Estonia, Finland, Germany, Greece, Hungary, 
Iceland, Ireland, Italy, Latvia, the Netherlands, Norway, 
Slovakia, Spain, Sweden and the United Kingdom) reported 
that that there had been no cases of suspended marketing 
authorization in respect to furanylfentanyl as a human 
medicine.
Twenty countries (Austria, Belgium, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, 
Latvia, the Netherlands, Norway, Poland, Portugal, Slovakia, 
Slovenia, Spain and Sweden) reported that that there had 
been no cases of suspended marketing authorization in 
respect to furanylfentanyl as a veterinary medicine.
The EMA also reported that furanylfentanyl is not the subject 
of a suspended marketing authorization for neither human nor 
veterinary use through the centralized procedure.
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I 5. Conclusion
Furanylfentanyl is a synthetic opioid. It is closely related to 
fentanyl, which is controlled under the United Nations Single 
Convention on Narcotic Drugs of 1961. Data suggests that 
furanylfentanyl is likely to be a potent opioid narcotic analgesic 
and may have an abuse liability and dependence potential in 
humans; these effects may be broadly comparable to fentanyl.
Furanylfentanyl has been available in the European Union 
since at least June 2015 and has been detected in 16 Member 
States and Norway. In most cases it has been seized as 
a powder, but other forms such as liquids, tablets, and herbal 
material have also been detected. The detected quantities are 
relatively small; however, they should be seen within the 
context of the high potency of the substance.
There are indications that the furanylfentanyl currently 
available on the market is synthesised by chemical companies 
based in China. Furanylfentanyl is sold online often under the 
guise of a ‘research chemical’. It is available in wholesale 
amounts up to 5 kilograms and in consumer amounts. In the 
latter case, these include ready-to-use nasal sprays. There is 
one report that indicates that furanylfentanyl was synthesised 
in a clandestine laboratory in Europe in 2013.
Nineteen deaths associated with furanylfentanyl have been 
reported by 4 Member States and Norway, all of which were 
analytically confirmed. 90% of the deaths occurred during 
2016. In at least 9 of the deaths furanylfentanyl was the cause 
of death or contributed to the death.
Information on the use of furanylfentanyl in Europe is limited. 
It appears that furanylfentanyl is used as a drug in its own 
right. However, serious concerns exist that the substance 
could be supplied surreptitiously to a range of drug users, 
including those who inject opioids.
Furanylfentanyl is not currently under assessment and has not 
been under assessment by the UN system. Furanylfentanyl is 
not subject to control measures in 16 Member States.
We conclude that the health and social risks caused by the 
manufacture, trafficking and use of furanylfentanyl, and the 
involvement of organised crime and possible consequences of 
control measures, could be thoroughly assessed through 
a risk assessment procedure in accordance with Article 6 of 
Council Decision 2005/387/JHA.
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I  Annex 1 Images from seizures and collected samples provided to the EMCDDA
Country Image Description
Cyprus Seizure
Date: 19 August 2016
White powder, 0,87 grams
Seizing authority: Police at Limassol
France Collected sample
Date: 14 October 2016
Nasal spray
Collecting authority: OFDT, SINTES – test 
purchase
France Collected sample
Date: 17 October 2016
E-liquid
Collecting authority: OFDT, SINTES – test 
purchase
Slovenia Collected sample
Date: 12 December 2017
Off-white powder
Collecting authority: Slovenian National 
Forensic Laboratory – test purchase in 
the frame of EU co-funded project 
RESPONSE
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I  Annex 2 Images provided to Europol
Country Image Description
Czech Republic Seizure
Plastic zip lock
Slovenia Collected sample
Collecting authority: Slovenian National 
Forensic Laboratory – test purchase in the 
frame of EU co-funded project RESPONSE
Norway Seizure recovered from a scene of death
‘Liquid Xanax’
‘Most likely contained furanylfentanyl’
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